- Analysts at Roth Capital and Craig-Hallum initiate coverage of Durata Therapeutics (DRTX) with BUY ratings. Both have a price target of $20.
- Nine analysts have ratings on the stock, seven bullish and two neutral.
- The company's lead product is delbavancin, an IV antibacterial for adult patients with acute skin and skin structure infections caused by Gram-positive bacteria.
- 79 mutual funds have positions, up from 68 a year earlier.
- Shares currently exchange hands at $14.